en Original Research <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Aims:</span></span></span></b> <span cambria="" style="font-family:">This study calculated the effects on serum chloride levels after treatment with erythropoietin and the antioxidant lazaroid (U-74389G). The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence after the respective drug usage in an induced ischemia-reperfusion animal experiment<span style="background:white">.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Materials & Methods:</span></span></span></b> <span cambria="" style="font-family:">The 2 main experimental endpoints at which the serum chloride levels were evaluated were the 60th reperfusion min (for groups A, C, and E) and the 120th reperfusion min (for groups B, D, and F). Groups A and B were processed without drugs, C and D after the erythropoietin administration, and E and F after the antioxidant lazaroid administration<span style="background:white">.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Findings:</span></span></span></b> <span cambria="" style="font-family:">The first preliminary study of erythropoietin presented a non-significant hypochloremic effect by 0.74+0.55% (p=0.1701). However, the second preliminary study of U-74389G showed a significant hypochloremic effect by 0.75+0.34% (p=0.031). These two studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that antioxidant lazaroid is 1.012762-fold (1.011746-1.01378) more hypochloremic than erythropoietin (p=0.0001)<span style="background:white">.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Conclusion:</span></span></span></b> <span cambria="" style="font-family:">The antioxidant capacities of U-74389G ascribe 1.012762-fold more hypochloremic effects than erythropoietin<span style="background:white">.</span></span></span></span></span><br> &nbsp; Ischemia, Erythropoietin, U-74389G, Serum Chloride Levels, Reperfusion 93 97 http://gmedicine.de/browse.php?a_code=A-10-1-63&slc_lang=en&sid=2 C. Τsompos 10031947532846001297 10031947532846001297 Yes Department of Gynecology, General Hospital of Thessaloniki C. Panoulis 10031947532846001298 10031947532846001298 No Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Athens, Attiki, Hellas K. Τοutouzas 10031947532846001299 10031947532846001299 No Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas A. Triantafyllou 10031947532846001300 10031947532846001300 No Department of Biologic Chemistry, Athens University, Athens, Attiki, Hellas G.C. Zografos 10031947532846001301 10031947532846001301 No Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas K. Tsarea 10031947532846001302 10031947532846001302 No Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Hellas M. Karamperi 10031947532846001303 10031947532846001303 No Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Hellas A. Papalois 10031947532846001304 10031947532846001304 No Educational and Research Center ELPEN European University Cyprus, School of Medicine, Cyprus